News provided by Eli Lilly and Company May 21, 2026, 06:45 ET In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving 30% weight loss, a level long associated with bariatric surgery Individuals with a baseline BMI 35 who participated in a study extension continued to lose weight, and achieved up to an average of 85.0 lbs (30.3%) weight loss at 104 weeks At the 4 mg dose, reached with only a single escalation step, participants lost an average of 47.2 lbs (19.0%) at 80 weeks with a lower observed discontinuation rate due to adverse events vs
The savings are meaningful, and unlike compounded alternatives, the product behind that price is fully regulated
In rare cases, injection site reactions like redness, swelling, or irritation can occur, requiring additional care and attention
Introductory Vial for 8 week Treatment
AthaudaDMaclaganKBudnikNZampedriLHibbertSAviles-OlmosIet al
The proportions of participants on additional concomitant and rescue glucose-lowering medication were low and similar across all treatment groups
